Clinical Trial Update: Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age [Phase 2]

View source ↗

Summary

Phase 2 pediatric trial evaluating tolerability, PK/PD and safety of dabigatran etexilate oral liquid in infants under 1 year; study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED | Results posted: 2016-09-20